Login to Your Account



THIRD SHIRE DEAL IN FIVE WEEKS

Amid M&A rumors, Shire widens Argen-x pact in rare disease space

By Nuala Moran
Staff Writer

Thursday, June 5, 2014

LONDON – Argen-x BV agreed to a third antibody discovery and development agreement with Shire plc, for the first time receiving an up-front payment from the rare diseases specialist.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription